Product Name

Zalcitabine

Name: Zalcitabine - LGM Pharma
SKU: 7481-89-2

CAS Number

7481-89-2

LGM Pharma is an API distributor. LGM Pharma can supply CGMP and/or DMF products, subject to availability and manufacturer requirements. LGM Pharma does not sell or supply APIs or finished dosage products to individual patients, doctors, pharmacies, or any pharmaceutical companies.

Questions? Call our customer API support number 1-(800)-881-8210

Product Name:

Zalcitabine

CAS Number:

7481-89-2

Indication:

For the treatment of Human immunovirus (HIV) infections in conjunction with other antivirals.

Mode of Action:

Zalcitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Within cells, zalcitabine is converted to its active metabolite, dideoxycytidine 5'-triphosphate (ddCTP), by the sequential action of cellular enzymes. ddCTP interferes with viral RNA-directed DNA polymerase (reverse transcriptase) by competing for utilization of the natural substrate deoxycytidine 5'-triphosphate (dCTP), as well as incorpating into viral DNA. Due to it's lack of a 3'-OH group, the formation of a 5' to 3' phosphodiester linkage that is necessary for DNA chain elongation is inhibited, thus leading to the termination of viral DNA growth.

Pharmacodynamics:

Zalcitabine is an analog of 2'-deoxycytidine that is pharmacologically related to but structurally different from other nucleotide reverse transcriptase inhibitors (NRTIs). Zalcitabine inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA.

Metabolism:

Hepatic

Toxicity:

Acute overdose: Inadvertent pediatric overdoses have occurred with doses up to 1.5 mg/kg zalcitabine. Chronic overdose: in an initial dose-finding study in which zalcitabine was administered at doses 25 times (0.25 mg/kg every 8 hours) the currently recommended dose, one patient discontinued zalcitabine after 1_ weeks of treatment subsequent to the development of a rash and fever.

IUPAC:

4-amino-1-[(2R, 5S)-5-(hydroxymethyl)oxolan-2-yl]-1, 2-dihydropyrimidin-2-one

ATC:

J05AF03

PubChem:

24066

DrugBank:

DB00943 (APRD00562)

Formula:

C₁₇H₁₅N₅O

Molecular Mass:

211.2178

Synonyms:

DDC DDCYD Dideoxycytidine

SMILES:

NC1=NC(=O)N(C=C1)[C@H]1CC[C@@H](CO)O1

InChi:

WREGKURFCTUGRC-POYBYMJQSA-N

General Reference:

Shelton MJ, OêDonnell AM, Morse GD: Zalcitabine. Ann Pharmacother. 1993 Apr;27(4):480-9. Pubmed
Devineni D, Gallo JM: Zalcitabine. Clinical pharmacokinetics and efficacy. Clin Pharmacokinet. 1995 May;28(5):351-60. Pubmed 7614775

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

LGM currently offers Monoclonal Antibodies (mAbs) for non-GMP/R&D use. Please inquire about Monoclonal Antibodies produced under GMP conditions.

Questions? Call our customer API support number 1-(800)-881-8210.

Ask us about this product

API’s From Quality Manufacturers:

Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
Premium quality GMP certified and fully accredited API manufacturing plants
Technical packages as well as access to filed DMF, ASMF or CEP (subject to availability)
Regulatory and technical assistance towards any submission type based on specific customer requirements

Zalcitabine

7481-89-2

Ask us about this product

API’s From Quality Manufacturers:

Find an API Product